A randomised controlled trial of 225 versus 300 IU recombinant follicle stimulating hormone (FSH) for ovarian stimulation in predicted normal responders by antral follicle count.

Trial Profile

A randomised controlled trial of 225 versus 300 IU recombinant follicle stimulating hormone (FSH) for ovarian stimulation in predicted normal responders by antral follicle count.

Completed
Phase of Trial: Phase III

Latest Information Update: 13 Oct 2015

At a glance

  • Drugs Follitropin alfa (Primary)
  • Indications Infertility
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Mar 2010 Primary endpoint 'Number of oocytes' has not been met.
    • 29 Mar 2010 Results published in BJOG: An International Journal of Obstetrics and Gynaecology.
    • 01 Dec 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top